Insilico Medicine publishes clinical data showing AI-designed rentosertib rejuvenates patients
Insilico Medicine published results from a phase 2a clinical trial of rentosertib, a TNIK inhibitor designed by AI for treating idiopathic pulmonary fibrosis, in Nature Biotechnology. The study tracked six proteomic aging clocks and found that rentosertib consistently reduced biological age in treated patients. The work demonstrates a novel approach to measuring drug effects on aging in clinical trials.
We live generally in prosperity. We're better off than ever before and living longer. But unfortunately, longer life doesn't always mean better quality of life. Insilico Medicine views aging as a disease that can be treated or at least have its effects mitigated.
What is rentosertib and what is it designed for?
Rentosertib is a TNIK inhibitor (targeting TRAF2- and NCK-interacting kinase) designed by artificial intelligence. It serves a dual purpose: treating idiopathic pulmonary fibrosis and slowing aging. TNIK was identified as a gene involved in six aging hallmarks.
What is the difference between epigenetic and proteomic aging clocks?
Epigenetic clocks measure DNA methylation but their clinical trial readouts are often inconsistent and difficult to interpret. Proteomic clocks track the immediate effectors of biological processes and may provide better biomarkers of aging and mechanistic insight through pathway analysis.
What were the main findings from the rentosertib study?
All six proteomic aging clocks consistently predicted lower biological age in patients treated with rentosertib. Pathway analysis additionally suggested the drug has potential anti-aging effects alongside its anti-fibrotic activity.
- AI detects hidden heart disease from routine ECG in just 2 seconds — firstpost.com 71 % match
- Cancer-fighting chewing gum cuts HPV levels by up to 93% — sciencedaily.com 71 % match
- Researchers develop electronic skin to sense temperature and pressure — news.wsu.edu 70 % match
- Insilico Medicine
- rentosertib
- Nature Biotechnology
- TNIK
- ProtAge
- UK Biobank